Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Myeloid, Acute | 63 | 2024 | 3609 | 9.850 |
Why?
|
Myelodysplastic Syndromes | 41 | 2024 | 1393 | 6.860 |
Why?
|
Sulfonamides | 13 | 2024 | 1977 | 2.320 |
Why?
|
Primary Myelofibrosis | 4 | 2021 | 208 | 2.260 |
Why?
|
Azacitidine | 11 | 2024 | 336 | 2.050 |
Why?
|
Leukocytosis | 5 | 2020 | 251 | 2.020 |
Why?
|
Hematopoietic Stem Cell Transplantation | 16 | 2024 | 5666 | 1.950 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 20 | 2024 | 11733 | 1.550 |
Why?
|
Antimetabolites, Antineoplastic | 7 | 2019 | 646 | 1.530 |
Why?
|
Salvage Therapy | 5 | 2023 | 1264 | 1.390 |
Why?
|
Leukemia, Promyelocytic, Acute | 2 | 2019 | 249 | 1.180 |
Why?
|
Leukapheresis | 4 | 2020 | 134 | 1.090 |
Why?
|
Cytarabine | 5 | 2024 | 697 | 1.060 |
Why?
|
Isocitrate Dehydrogenase | 5 | 2024 | 937 | 1.040 |
Why?
|
Interferon-alpha | 2 | 2020 | 907 | 1.040 |
Why?
|
Remission Induction | 7 | 2024 | 2392 | 0.970 |
Why?
|
Immunologic Factors | 3 | 2019 | 1589 | 0.920 |
Why?
|
Chromosome Inversion | 1 | 2024 | 119 | 0.890 |
Why?
|
Thrombocythemia, Essential | 2 | 2024 | 113 | 0.870 |
Why?
|
DNA Methylation | 7 | 2024 | 4384 | 0.870 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2024 | 322 | 0.860 |
Why?
|
Mutation | 20 | 2024 | 30002 | 0.840 |
Why?
|
Graft vs Host Disease | 5 | 2023 | 3025 | 0.830 |
Why?
|
Leukemia | 4 | 2024 | 1518 | 0.770 |
Why?
|
Histone Deacetylase Inhibitors | 2 | 2017 | 774 | 0.740 |
Why?
|
Neoplasms, Second Primary | 3 | 2024 | 1052 | 0.720 |
Why?
|
fms-Like Tyrosine Kinase 3 | 5 | 2024 | 495 | 0.680 |
Why?
|
Tretinoin | 2 | 2019 | 517 | 0.670 |
Why?
|
Disease Management | 7 | 2024 | 2507 | 0.660 |
Why?
|
Hydroxyurea | 1 | 2020 | 284 | 0.650 |
Why?
|
Immunotherapy | 8 | 2023 | 4642 | 0.640 |
Why?
|
Carcinogens | 1 | 2021 | 452 | 0.640 |
Why?
|
Polycythemia Vera | 1 | 2020 | 161 | 0.630 |
Why?
|
Pyrazoles | 3 | 2018 | 2010 | 0.590 |
Why?
|
Humans | 111 | 2024 | 761208 | 0.550 |
Why?
|
Myeloproliferative Disorders | 5 | 2024 | 609 | 0.540 |
Why?
|
Leukemia, Neutrophilic, Chronic | 1 | 2016 | 13 | 0.530 |
Why?
|
Receptors, Colony-Stimulating Factor | 1 | 2016 | 50 | 0.530 |
Why?
|
Neutropenia | 1 | 2021 | 885 | 0.520 |
Why?
|
Transplantation Conditioning | 3 | 2023 | 1591 | 0.520 |
Why?
|
Nuclear Proteins | 4 | 2024 | 5782 | 0.500 |
Why?
|
Hypereosinophilic Syndrome | 1 | 2016 | 97 | 0.500 |
Why?
|
Janus Kinase 2 | 2 | 2024 | 559 | 0.490 |
Why?
|
Prognosis | 21 | 2024 | 29687 | 0.480 |
Why?
|
Steroids | 1 | 2019 | 929 | 0.460 |
Why?
|
Hematinics | 1 | 2017 | 282 | 0.460 |
Why?
|
Culture | 1 | 2018 | 623 | 0.460 |
Why?
|
Molecular Targeted Therapy | 8 | 2024 | 2813 | 0.450 |
Why?
|
Epigenesis, Genetic | 5 | 2024 | 3788 | 0.450 |
Why?
|
DNA, Neoplasm | 1 | 2019 | 1743 | 0.440 |
Why?
|
Interferons | 1 | 2017 | 702 | 0.430 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2015 | 450 | 0.410 |
Why?
|
Thalidomide | 2 | 2017 | 885 | 0.400 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2016 | 726 | 0.400 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2023 | 2131 | 0.400 |
Why?
|
Antineoplastic Agents | 8 | 2024 | 13632 | 0.400 |
Why?
|
Lymphoma | 1 | 2021 | 1898 | 0.390 |
Why?
|
Hemorrhage | 2 | 2024 | 3422 | 0.390 |
Why?
|
Thiazolidines | 1 | 2011 | 69 | 0.390 |
Why?
|
Hematologic Neoplasms | 3 | 2018 | 1895 | 0.370 |
Why?
|
Glyburide | 1 | 2011 | 116 | 0.360 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2019 | 9278 | 0.360 |
Why?
|
Transplantation, Homologous | 6 | 2023 | 4822 | 0.350 |
Why?
|
Glycine | 2 | 2024 | 659 | 0.350 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 1549 | 0.340 |
Why?
|
Benzoates | 1 | 2011 | 211 | 0.340 |
Why?
|
Hydrazines | 1 | 2011 | 222 | 0.340 |
Why?
|
Drug Delivery Systems | 1 | 2021 | 2223 | 0.340 |
Why?
|
Androgens | 1 | 2017 | 1283 | 0.330 |
Why?
|
Neoplasms | 7 | 2023 | 22140 | 0.330 |
Why?
|
Tumor Suppressor Protein p53 | 6 | 2024 | 2915 | 0.330 |
Why?
|
Antiviral Agents | 2 | 2022 | 3048 | 0.320 |
Why?
|
Retrospective Studies | 17 | 2024 | 80674 | 0.310 |
Why?
|
Neoplasm, Residual | 3 | 2022 | 1008 | 0.300 |
Why?
|
Treatment Outcome | 18 | 2024 | 64681 | 0.300 |
Why?
|
Clinical Trials as Topic | 9 | 2024 | 8003 | 0.300 |
Why?
|
Nitriles | 3 | 2018 | 971 | 0.290 |
Why?
|
Cell Cycle Proteins | 3 | 2024 | 3446 | 0.290 |
Why?
|
Chromosomal Proteins, Non-Histone | 2 | 2024 | 725 | 0.280 |
Why?
|
Antilymphocyte Serum | 2 | 2019 | 491 | 0.280 |
Why?
|
Daunorubicin | 2 | 2024 | 157 | 0.280 |
Why?
|
Combined Modality Therapy | 4 | 2024 | 8519 | 0.260 |
Why?
|
Disease-Free Survival | 4 | 2020 | 6819 | 0.260 |
Why?
|
Chromosomes, Human, Pair 5 | 2 | 2017 | 386 | 0.250 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 1746 | 0.250 |
Why?
|
Aged | 26 | 2024 | 169288 | 0.240 |
Why?
|
Standard of Care | 2 | 2019 | 550 | 0.230 |
Why?
|
Drug Therapy, Combination | 4 | 2019 | 6304 | 0.230 |
Why?
|
Thrombocytosis | 1 | 2024 | 88 | 0.230 |
Why?
|
Attitude of Health Personnel | 1 | 2018 | 3885 | 0.230 |
Why?
|
Benzothiazoles | 1 | 2024 | 248 | 0.210 |
Why?
|
Cell Differentiation | 2 | 2024 | 11509 | 0.210 |
Why?
|
Myelodysplastic-Myeloproliferative Diseases | 1 | 2022 | 15 | 0.210 |
Why?
|
Adult | 22 | 2024 | 221119 | 0.210 |
Why?
|
Survival Analysis | 4 | 2018 | 10088 | 0.200 |
Why?
|
Aged, 80 and over | 13 | 2024 | 58952 | 0.190 |
Why?
|
Anthracyclines | 1 | 2023 | 285 | 0.190 |
Why?
|
Middle Aged | 21 | 2024 | 220853 | 0.180 |
Why?
|
Drug Design | 2 | 2016 | 1045 | 0.180 |
Why?
|
Cytogenetic Analysis | 1 | 2021 | 270 | 0.180 |
Why?
|
Phenylurea Compounds | 1 | 2024 | 529 | 0.180 |
Why?
|
Pyrimidines | 3 | 2018 | 3027 | 0.180 |
Why?
|
Pteridines | 1 | 2020 | 47 | 0.180 |
Why?
|
Leukostasis | 1 | 2020 | 23 | 0.180 |
Why?
|
Survival Rate | 5 | 2024 | 12728 | 0.170 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2024 | 1404 | 0.170 |
Why?
|
Hematology | 1 | 2023 | 243 | 0.170 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2023 | 677 | 0.160 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2021 | 10218 | 0.160 |
Why?
|
Telomerase | 1 | 2024 | 741 | 0.160 |
Why?
|
Nuclear Pore Complex Proteins | 1 | 2020 | 163 | 0.160 |
Why?
|
Stem Cell Transplantation | 3 | 2022 | 1600 | 0.160 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2021 | 355 | 0.160 |
Why?
|
Idiopathic Pulmonary Fibrosis | 1 | 2024 | 514 | 0.150 |
Why?
|
Male | 23 | 2024 | 360693 | 0.150 |
Why?
|
Prednisolone | 1 | 2018 | 324 | 0.140 |
Why?
|
Tumor Escape | 2 | 2020 | 371 | 0.140 |
Why?
|
Hematopoiesis | 2 | 2024 | 2046 | 0.140 |
Why?
|
Patients | 1 | 2023 | 906 | 0.140 |
Why?
|
Anemia, Macrocytic | 1 | 2017 | 53 | 0.140 |
Why?
|
Chromosome Aberrations | 1 | 2023 | 1767 | 0.140 |
Why?
|
Pulmonary Edema | 1 | 2019 | 408 | 0.130 |
Why?
|
Incidence | 4 | 2024 | 21365 | 0.130 |
Why?
|
Female | 24 | 2024 | 392544 | 0.130 |
Why?
|
Databases, Factual | 2 | 2024 | 7966 | 0.130 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2024 | 1605 | 0.130 |
Why?
|
Leukocyte Count | 1 | 2020 | 1597 | 0.130 |
Why?
|
Immunosuppressive Agents | 2 | 2019 | 4190 | 0.130 |
Why?
|
Oncogene Proteins | 1 | 2020 | 718 | 0.130 |
Why?
|
Tumor Microenvironment | 3 | 2019 | 3873 | 0.130 |
Why?
|
Natriuretic Peptide, C-Type | 1 | 2015 | 19 | 0.130 |
Why?
|
Enzyme Inhibitors | 2 | 2024 | 3702 | 0.130 |
Why?
|
Paraneoplastic Syndromes | 1 | 2017 | 155 | 0.120 |
Why?
|
Recombinant Fusion Proteins | 1 | 2024 | 3726 | 0.120 |
Why?
|
Cancer Vaccines | 2 | 2020 | 1038 | 0.120 |
Why?
|
Granuloma | 1 | 2017 | 326 | 0.120 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 226 | 0.120 |
Why?
|
Immunomodulation | 1 | 2018 | 548 | 0.120 |
Why?
|
Patient Selection | 2 | 2017 | 4246 | 0.120 |
Why?
|
Erythrocyte Transfusion | 1 | 2019 | 569 | 0.110 |
Why?
|
Atrial Natriuretic Factor | 1 | 2015 | 350 | 0.110 |
Why?
|
Cost-Benefit Analysis | 2 | 2024 | 5493 | 0.110 |
Why?
|
Antibodies, Bispecific | 1 | 2016 | 196 | 0.110 |
Why?
|
Hypotension | 1 | 2019 | 879 | 0.110 |
Why?
|
Risk Assessment | 4 | 2023 | 24021 | 0.110 |
Why?
|
Skin | 2 | 2017 | 4473 | 0.110 |
Why?
|
Syndrome | 1 | 2019 | 3271 | 0.110 |
Why?
|
Immunotherapy, Adoptive | 2 | 2020 | 1468 | 0.100 |
Why?
|
Infection Control | 1 | 2020 | 983 | 0.100 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2015 | 481 | 0.100 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2451 | 0.100 |
Why?
|
Drug Discovery | 2 | 2019 | 1050 | 0.100 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7400 | 0.100 |
Why?
|
Amino Acid Substitution | 1 | 2017 | 1737 | 0.100 |
Why?
|
RNA Splicing | 3 | 2023 | 896 | 0.100 |
Why?
|
Chromatin | 1 | 2024 | 2946 | 0.100 |
Why?
|
Chromosome Deletion | 1 | 2017 | 1386 | 0.100 |
Why?
|
Developing Countries | 1 | 2024 | 2863 | 0.100 |
Why?
|
Squalus acanthias | 1 | 2011 | 5 | 0.100 |
Why?
|
Fundulidae | 1 | 2011 | 12 | 0.100 |
Why?
|
Xenopus laevis | 2 | 2015 | 962 | 0.090 |
Why?
|
Animals | 15 | 2024 | 168079 | 0.090 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2020 | 3634 | 0.090 |
Why?
|
Healthcare Disparities | 2 | 2024 | 3354 | 0.090 |
Why?
|
Recurrence | 2 | 2020 | 8457 | 0.090 |
Why?
|
Ventricular Function, Left | 1 | 2023 | 3899 | 0.090 |
Why?
|
Adolescent | 6 | 2024 | 88298 | 0.090 |
Why?
|
Counseling | 1 | 2018 | 1536 | 0.090 |
Why?
|
Oocytes | 1 | 2015 | 1165 | 0.090 |
Why?
|
Dendritic Cells | 1 | 2021 | 2726 | 0.080 |
Why?
|
Genotype | 1 | 2024 | 12985 | 0.080 |
Why?
|
Stroke Volume | 1 | 2023 | 5521 | 0.080 |
Why?
|
Internet | 2 | 2020 | 3096 | 0.080 |
Why?
|
Protein Kinase Inhibitors | 2 | 2024 | 5662 | 0.080 |
Why?
|
Skin Diseases | 1 | 2017 | 1095 | 0.080 |
Why?
|
Cohort Studies | 2 | 2024 | 41496 | 0.080 |
Why?
|
Mortality | 1 | 2019 | 2896 | 0.080 |
Why?
|
Proto-Oncogene Proteins | 1 | 2020 | 4513 | 0.070 |
Why?
|
Young Adult | 5 | 2024 | 59221 | 0.070 |
Why?
|
Mutation, Missense | 1 | 2017 | 2567 | 0.070 |
Why?
|
Gene Expression | 1 | 2020 | 7571 | 0.070 |
Why?
|
Immunity, Innate | 2 | 2018 | 3044 | 0.070 |
Why?
|
Odds Ratio | 1 | 2020 | 9652 | 0.070 |
Why?
|
Anemia | 1 | 2017 | 1504 | 0.070 |
Why?
|
Survivors | 1 | 2017 | 2369 | 0.070 |
Why?
|
Acute Kidney Injury | 1 | 2019 | 1923 | 0.070 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2016 | 2820 | 0.070 |
Why?
|
Quality-Adjusted Life Years | 2 | 2024 | 1723 | 0.070 |
Why?
|
Multivariate Analysis | 1 | 2020 | 12052 | 0.070 |
Why?
|
Histones | 1 | 2016 | 2570 | 0.070 |
Why?
|
Logistic Models | 1 | 2020 | 13249 | 0.060 |
Why?
|
Chronic Disease | 1 | 2020 | 9319 | 0.060 |
Why?
|
Risk Factors | 3 | 2024 | 74239 | 0.060 |
Why?
|
Risk | 1 | 2017 | 9616 | 0.060 |
Why?
|
Lymph Nodes | 1 | 2016 | 3461 | 0.060 |
Why?
|
Biopsy | 1 | 2016 | 6781 | 0.060 |
Why?
|
Interleukin-3 Receptor alpha Subunit | 1 | 2024 | 36 | 0.060 |
Why?
|
Chondroitin Sulfate Proteoglycans | 1 | 2024 | 141 | 0.060 |
Why?
|
Consensus | 2 | 2024 | 3134 | 0.060 |
Why?
|
Genome, Mitochondrial | 1 | 2024 | 67 | 0.060 |
Why?
|
Melanoma | 1 | 2022 | 5694 | 0.050 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2018 | 5300 | 0.050 |
Why?
|
Electrocardiography | 1 | 2016 | 6387 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2020 | 9187 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2019 | 15841 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2018 | 39126 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3093 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3215 | 0.050 |
Why?
|
Platelet Count | 1 | 2024 | 782 | 0.050 |
Why?
|
Prednisone | 2 | 2017 | 1565 | 0.050 |
Why?
|
Antigens, CD34 | 1 | 2024 | 655 | 0.050 |
Why?
|
Pyridines | 2 | 2024 | 2872 | 0.050 |
Why?
|
Quality of Life | 1 | 2023 | 13367 | 0.050 |
Why?
|
Developed Countries | 1 | 2024 | 448 | 0.050 |
Why?
|
Thymidine Kinase | 1 | 2022 | 286 | 0.050 |
Why?
|
Swine | 1 | 2011 | 5909 | 0.050 |
Why?
|
Ganciclovir | 1 | 2022 | 253 | 0.050 |
Why?
|
United States | 5 | 2022 | 72339 | 0.050 |
Why?
|
Blast Crisis | 1 | 2021 | 102 | 0.040 |
Why?
|
Methotrexate | 2 | 2018 | 1718 | 0.040 |
Why?
|
Clone Cells | 1 | 2024 | 1668 | 0.040 |
Why?
|
Tumor Lysis Syndrome | 1 | 2020 | 38 | 0.040 |
Why?
|
Disease Progression | 1 | 2017 | 13511 | 0.040 |
Why?
|
Megakaryocytes | 1 | 2024 | 566 | 0.040 |
Why?
|
Amino Acid Sequence | 1 | 2011 | 13402 | 0.040 |
Why?
|
Bone Marrow | 2 | 2023 | 2911 | 0.040 |
Why?
|
Introns | 1 | 2022 | 968 | 0.040 |
Why?
|
Uveal Neoplasms | 1 | 2022 | 341 | 0.040 |
Why?
|
Molecular Sequence Data | 1 | 2011 | 17598 | 0.040 |
Why?
|
Telomere | 1 | 2024 | 939 | 0.040 |
Why?
|
Time Factors | 1 | 2019 | 39957 | 0.040 |
Why?
|
Resource Allocation | 1 | 2020 | 350 | 0.040 |
Why?
|
Expert Testimony | 1 | 2020 | 365 | 0.040 |
Why?
|
Skin Diseases, Viral | 1 | 2017 | 26 | 0.040 |
Why?
|
Dermatomycoses | 1 | 2017 | 48 | 0.040 |
Why?
|
Epigenomics | 1 | 2023 | 944 | 0.040 |
Why?
|
Breast Neoplasms | 2 | 2022 | 20982 | 0.030 |
Why?
|
Skin Diseases, Bacterial | 1 | 2017 | 67 | 0.030 |
Why?
|
Histiocytes | 1 | 2017 | 98 | 0.030 |
Why?
|
Phosphoproteins | 1 | 2024 | 2444 | 0.030 |
Why?
|
Indoles | 1 | 2023 | 1830 | 0.030 |
Why?
|
Biological Therapy | 1 | 2016 | 139 | 0.030 |
Why?
|
Protein Processing, Post-Translational | 1 | 2023 | 1967 | 0.030 |
Why?
|
Tacrolimus | 1 | 2018 | 736 | 0.030 |
Why?
|
Prospective Studies | 1 | 2019 | 54435 | 0.030 |
Why?
|
Multiple Organ Failure | 1 | 2017 | 386 | 0.030 |
Why?
|
RNA | 1 | 2024 | 2709 | 0.030 |
Why?
|
SEER Program | 1 | 2019 | 1453 | 0.030 |
Why?
|
Fibroblasts | 1 | 2024 | 4137 | 0.030 |
Why?
|
RNA-Binding Proteins | 1 | 2022 | 1855 | 0.030 |
Why?
|
Vincristine | 1 | 2016 | 1036 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2022 | 2426 | 0.030 |
Why?
|
Adaptive Immunity | 1 | 2018 | 724 | 0.030 |
Why?
|
Signal Transduction | 1 | 2016 | 23416 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20588 | 0.030 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2020 | 1783 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2017 | 1838 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2020 | 1985 | 0.020 |
Why?
|
Inflammation | 2 | 2024 | 10759 | 0.020 |
Why?
|
Drug Approval | 1 | 2019 | 812 | 0.020 |
Why?
|
Hematopoietic Stem Cells | 1 | 2024 | 3388 | 0.020 |
Why?
|
Sirolimus | 1 | 2018 | 1540 | 0.020 |
Why?
|
Treatment Failure | 1 | 2017 | 2643 | 0.020 |
Why?
|
Medicare | 2 | 2019 | 6773 | 0.020 |
Why?
|
Thrombosis | 1 | 2024 | 2944 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2020 | 2194 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2019 | 1662 | 0.020 |
Why?
|
Blood Transfusion | 1 | 2017 | 1303 | 0.020 |
Why?
|
Lymphoma, B-Cell | 1 | 2016 | 938 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2018 | 1885 | 0.020 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2016 | 782 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2015 | 3577 | 0.020 |
Why?
|
Antigens, CD | 1 | 2019 | 4009 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6486 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 10756 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2024 | 7851 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2024 | 9566 | 0.020 |
Why?
|
Apoptosis | 1 | 2022 | 9477 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2024 | 11856 | 0.020 |
Why?
|
Health Personnel | 1 | 2020 | 3337 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2022 | 16952 | 0.020 |
Why?
|
Mice | 2 | 2024 | 81326 | 0.020 |
Why?
|
Lung | 1 | 2024 | 9979 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2019 | 4574 | 0.020 |
Why?
|
Pilot Projects | 1 | 2018 | 8642 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2019 | 12474 | 0.010 |
Why?
|
Neutrophils | 1 | 2017 | 3763 | 0.010 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2016 | 2223 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2024 | 26071 | 0.010 |
Why?
|
Cytokines | 1 | 2018 | 7386 | 0.010 |
Why?
|
Comorbidity | 1 | 2017 | 10516 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8663 | 0.010 |
Why?
|
Age Factors | 1 | 2016 | 18384 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2015 | 18926 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2017 | 20119 | 0.010 |
Why?
|